Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30901811 | 0.86 | PNMT (0.33) | PNMTCD44MAOBASIC3 | |
| SCHEMBL12490048 | 0.83 | PNMT (0.35) | PNMTCD44MAOBHTR6S1PR1 | |
| SCHEMBL16220603 | 0.74 | PNMT (0.38) | PNMTCD44MAOBHTR6S1PR1 | |
| SCHEMBL23641905 | 0.73 | HSD11B1 (0.31) | PNMTHTR2AHTR2C | |
| SCHEMBL15088358 | 0.73 | BPTF (0.39) | PNMTCD44MAOBHTR6S1PR1 | |
| SCHEMBL25520564 | 0.72 | S1PR1 (0.34) | PNMTCD44MAOBHTR6S1PR1 | |
| Hydrochloric Acid SCHEMBL3030341 | 0.71 | BPTF (0.39) | PNMTCD44MAOBHTR6S1PR1 | |
| Hydrochloric Acid SCHEMBL29759718 | 0.71 | BPTF (0.39) | PNMTCD44MAOBHTR6S1PR1 | |
| Trifluoroacetic Acid SCHEMBL29548579 | 0.71 | BPTF (0.35) | PNMTHTR6HTR2AHTR2C | |
| SCHEMBL21941336 | 0.70 | HTR6 (0.31) | HTR6S1PR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | PNMT 1329/4885CD44 4858/4885MAOB 219/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | PNMT 1329/4885CD44 4858/4885MAOB 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.